25 May 2021
RaDaR ctDNA liquid biopsy to monitor response of late-stage solid tumors to treatment
Inivata, a leader in liquid biopsy, today announced a collaboration with F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, for the use of Inivata’s RaDaR technology.
Under the collaboration, Inivata’s RaDaR technology, a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, will be applied to identify and evaluate potential early biomarkers of clinical efficacy.
Peter Collins, CBO of Inivata, commented:
This collaboration with F-star underlines the broad potential utility of our RaDaR technology. Through the highly sensitive detection of ctDNA with a personalized assay, RaDaR can provide early insights into the efficacy of drug candidates for solid tumors in individual patients and allow for more rapid and efficient clinical trials. We are excited to be working with F-star to support the clinical development of their highly innovative bispecific antibodies.